Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SAD/MAD/food-effect study of LND101001 in healthy volunteers
NL-OMON37192Phase 1Active, not recruiting
- Sponsor
- Lupin Limited
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of edonerpic in Alzheimer's disease (AD) and Dementia (3 arms), sponsored by Lupin Limited. Primary endpoints: Pharmacokinetics of LND101001 after single ascending doses, Pharmacokinetics of LND101001 after multiple ascending doses and 1 more. Started Nov 2012; status: active, not recruiting.
02
Drugs
edonerpic
03
Conditions
Alzheimer's disease (AD)Dementia
Beyond the preview
Go deeper on NL-OMON37192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37192.